331 related articles for article (PubMed ID: 37980602)
21. Mitochondrial degeneration precedes the development of muscle atrophy in progression of cancer cachexia in tumour-bearing mice.
Brown JL; Rosa-Caldwell ME; Lee DE; Blackwell TA; Brown LA; Perry RA; Haynie WS; Hardee JP; Carson JA; Wiggs MP; Washington TA; Greene NP
J Cachexia Sarcopenia Muscle; 2017 Dec; 8(6):926-938. PubMed ID: 28845591
[TBL] [Abstract][Full Text] [Related]
22. Muscle alterations in the development and progression of cancer-induced muscle atrophy: a review.
Rosa-Caldwell ME; Fix DK; Washington TA; Greene NP
J Appl Physiol (1985); 2020 Jan; 128(1):25-41. PubMed ID: 31725360
[TBL] [Abstract][Full Text] [Related]
23. The importance of biological sex in cardiac cachexia.
Holder ER; Alibhai FJ; Caudle SL; McDermott JC; Tobin SW
Am J Physiol Heart Circ Physiol; 2022 Oct; 323(4):H609-H627. PubMed ID: 35960634
[TBL] [Abstract][Full Text] [Related]
24. Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse.
Aulino P; Berardi E; Cardillo VM; Rizzuto E; Perniconi B; Ramina C; Padula F; Spugnini EP; Baldi A; Faiola F; Adamo S; Coletti D
BMC Cancer; 2010 Jul; 10():363. PubMed ID: 20615237
[TBL] [Abstract][Full Text] [Related]
25. Muscle Atrophy in Cancer.
Yang J; Cao RY; Li Q; Zhu F
Adv Exp Med Biol; 2018; 1088():329-346. PubMed ID: 30390259
[TBL] [Abstract][Full Text] [Related]
26. Muscle wasting in cancer and ageing: cachexia versus sarcopenia.
Argilés JM; Busquets S; Felipe A; López-Soriano FJ
Adv Gerontol; 2006; 18():39-54. PubMed ID: 16676797
[TBL] [Abstract][Full Text] [Related]
27. Impaired Muscle Regeneration in Cancer-Associated Cachexia.
Arneson PC; Doles JD
Trends Cancer; 2019 Oct; 5(10):579-582. PubMed ID: 31706505
[TBL] [Abstract][Full Text] [Related]
28. F-BOX proteins in cancer cachexia and muscle wasting: Emerging regulators and therapeutic opportunities.
Sukari A; Muqbil I; Mohammad RM; Philip PA; Azmi AS
Semin Cancer Biol; 2016 Feb; 36():95-104. PubMed ID: 26804424
[TBL] [Abstract][Full Text] [Related]
29. The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia.
Bonetto A; Rupert JE; Barreto R; Zimmers TA
J Vis Exp; 2016 Nov; (117):. PubMed ID: 27929469
[TBL] [Abstract][Full Text] [Related]
30. Phenotypic features of cancer cachexia-related loss of skeletal muscle mass and function: lessons from human and animal studies.
Martin A; Freyssenet D
J Cachexia Sarcopenia Muscle; 2021 Apr; 12(2):252-273. PubMed ID: 33783983
[TBL] [Abstract][Full Text] [Related]
31. FoxP1 is a transcriptional repressor associated with cancer cachexia that induces skeletal muscle wasting and weakness.
Neyroud D; Nosacka RL; Callaway CS; Trevino JG; Hu H; Judge SM; Judge AR
J Cachexia Sarcopenia Muscle; 2021 Apr; 12(2):421-442. PubMed ID: 33527776
[TBL] [Abstract][Full Text] [Related]
32. Cancer-Induced Muscle Wasting Requires p38β MAPK Activation of p300.
Sin TK; Zhang G; Zhang Z; Zhu JZ; Zuo Y; Frost JA; Li M; Li YP
Cancer Res; 2021 Feb; 81(4):885-897. PubMed ID: 33355181
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of metabolic dysfunction in cancer-associated cachexia.
Petruzzelli M; Wagner EF
Genes Dev; 2016 Mar; 30(5):489-501. PubMed ID: 26944676
[TBL] [Abstract][Full Text] [Related]
34. Mitochondrial plasticity in cancer-related muscle wasting: potential approaches for its management.
Vitorino R; Moreira-Gonçalves D; Ferreira R
Curr Opin Clin Nutr Metab Care; 2015 May; 18(3):226-33. PubMed ID: 25783794
[TBL] [Abstract][Full Text] [Related]
35. Skeletal muscle is enriched in hematopoietic stem cells and not inflammatory cells in cachectic mice.
Berardi E; Aulino P; Murfuni I; Toschi A; Padula F; Scicchitano BM; Coletti D; Adamo S
Neurol Res; 2008 Mar; 30(2):160-9. PubMed ID: 18397608
[TBL] [Abstract][Full Text] [Related]
36. Pathophysiology of peripheral muscle wasting in cardiac cachexia.
Filippatos GS; Anker SD; Kremastinos DT
Curr Opin Clin Nutr Metab Care; 2005 May; 8(3):249-54. PubMed ID: 15809526
[TBL] [Abstract][Full Text] [Related]
37. Amiloride ameliorates muscle wasting in cancer cachexia through inhibiting tumor-derived exosome release.
Zhou L; Zhang T; Shao W; Lu R; Wang L; Liu H; Jiang B; Li S; Zhuo H; Wang S; Li Q; Huang C; Lin D
Skelet Muscle; 2021 Jul; 11(1):17. PubMed ID: 34229732
[TBL] [Abstract][Full Text] [Related]
38. Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system.
Op den Kamp CM; Langen RC; Minnaard R; Kelders MC; Snepvangers FJ; Hesselink MK; Dingemans AC; Schols AM
Lung Cancer; 2012 Apr; 76(1):112-7. PubMed ID: 22018880
[TBL] [Abstract][Full Text] [Related]
39. Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model.
Hanada K; Fukasawa K; Hinata H; Imai S; Takayama K; Hirai H; Ohfusa R; Hayashi Y; Itoh F
Cancer Sci; 2022 Oct; 113(10):3547-3557. PubMed ID: 35849084
[TBL] [Abstract][Full Text] [Related]
40. Reduced rDNA transcription diminishes skeletal muscle ribosomal capacity and protein synthesis in cancer cachexia.
Kim HG; Huot JR; Pin F; Guo B; Bonetto A; Nader GA
FASEB J; 2021 Feb; 35(2):e21335. PubMed ID: 33527503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
